Effect of Daily Fiber Intake Among Cirrhotic Patients With and Without Portosystemic Shunts by Simona Parisse, Sara Carnevale, Elio Damato, Flaminia Ferri, Monica Mischitelli, Mario Corona, Pierleone Lucatelli, Alfredo Cantafora, Adriano De Santis, Domenico Alvaro, Maurizio Muscaritoli, Stefano Ginanni Corradini

“…Methods: Daily soluble and insoluble fiber intake was extrapolated from 3-d food diaries in 25 patients with chronic hepatitis (CH) and 80 CIRs outpatient liver transplant candidates abstinent from alcohol and nonviremic for ≥6 mo. …”
Get full text

Clarithromycin-Associated Acute Liver Failure Leading to Fatal, Massive Upper Gastrointestinal Hemorrhage from Profound Coagulopathy: Case Report and Systematic Literature Review by Ahmed I. Edhi, Seifeldin Hakim, Christienne Shams, Damanpreet Bedi, Mitual Amin, Mitchell S. Cappell

“…A new case of clarithromycin-associated ALF is reported with hepatic histopathology and exclusion of other etiologies by extensive workup, and the syndrome of clarithromycin-associated ALF is better characterized by systematic review. …”
Get full text

Racial and ethnic differences in fatal child abuse and neglect and the intersection of community poverty: U.S., 2003 to 2022 by Rebecca F. Wilson, Xin Yue, Karen E. Thomas, Krishna Kiran Kota, Carter J. Betz

Get full text

Successful Endoscopic Injection Sclerotherapy of High-Risk Gastroesophageal Varices in a Cirrhotic Patient with Hemophilia A by Kohei Fukumoto, Hideyuki Konishi, Koichi Soga, Ki-ichiro Miyawaki, Hitoshi Okano, Masahito Minami, Naoki Wakabayashi, Shoji Mitsufuji, Norimasa Yoshida, Tomohisa Takagi, Nobuaki Yagi, Yuji Naito, Keisho Kataoka, Toshikazu Yoshikawa

“…A 68-year-old man with hemophilia A and liver cirrhosis caused by hepatitis C virus was referred to our hospital to receive prophylactic endoscopic treatment for gastroesophageal varices (GOV). …”
Get full text

Single‐cell landscape of the intrahepatic ecosystem in alcohol‐related liver disease by Xiaofang Zhao, Senyan Wang, Qi Liu, Wenjuan Wei, Xiaoyan Sun, Hao Song, Jing Xu, Shuijun Zhang, Hongyang Wang, Jing Fu

“…In addition, our results also uncovered the important alterations of nonparenchymal cells, especially macrophages and T/NK populations that responsible for active inflammation responses in alcohol‐related hepatitis and immunosuppressive microenvironment in advanced cirrhosis livers, which likely facilitated the malignant progression of ALD. …”
Get full text

Ginsenoside Rg1: A bioactive therapeutic agent for diverse liver diseases by Mingyu Wu, Ke Li, Jiabin Wu, Xianyi Ding, Xiaotong Ma, Wenhong Wang, Weihua Xiao

“…As a kind of monomer in Chinese medicine with multitarget pharmacological effects, G-Rg1 can provide significant therapeutic benefits in the alleviation of alcoholic liver disease, nonalcoholic fatty liver disease, liver fibrosis, viral hepatitis, etc., which mainly rely on the inhibition of apoptosis, strengthening endogenous anti-inflammatory and antioxidant mechanisms, activation of immune responses and regulation of efflux transport signals, to improve pathological changes in the liver caused by lipid deposition, inflammation, oxidative stress, accumulation of hepatotoxic product, etc. …”
Get full text

Chemical Characterization and Differential Lipid-Modulating Effects of Selected Plant Extracts from Côa Valley (Portugal) in a Cell Model for Liver Steatosis by Ricardo Amorim, Mário Pedro Marques, Catarina Melim, Carla Varela, Vilma A. Sardão, José Teixeira, Maria Inês Dias, Lillian Barros, Paulo J. Oliveira, Célia Cabral

“…(hemorrhages, urethritis, hepatitis), <i>Rumex scutatus</i> L. subsp. <i>induratus</i> (Boiss. and Reut.) …”
Get full text

Endothelial Dysfunction Correlates with Liver Fibrosis in Chronic HCV Infection by Michele Barone, Maria Teresa Viggiani, Annabianca Amoruso, Serafina Schiraldi, Annapaola Zito, Fiorella Devito, Francesca Cortese, Michele Gesualdo, Natale Brunetti, Alfredo Di Leo, Pietro Scicchitano, Marco Matteo Ciccone

“…Background. Hepatitis C virus (HCV) infection can exert proatherogenic activities due to its direct action on vessel walls and/or via the chronic inflammatory process involving the liver. …”
Get full text

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure by Davide Scalabrini, Paolo Sciuto, Cristina Felicani, Antonia Rudilosso, Pietro Andreone

“…This article reports two different cases concerning respectively an 83-year-old female patient suffering from arterial hypertension, aneurysm of the sub-renal aorta, hepatitis C virus (HCV)-positive liver cirrhosis responsive to treatment with antiviral drugs, and a 2.0 cm diameter hepatocellular carcinoma (HCC) nodule localized in the hepatic segment III and a 53-year-old female patient with HCV-positive liver cirrhosis complicated by portal hypertension with splenomegaly, thrombocytopenia, and F3 esophageal varices at high risk of bleeding. …”
Get full text

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study by Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu

“…Results The study included 70 patients with unresectable HCC, predominantly male and infected with Hepatitis B. The median follow-up duration for the whole cohort was 13.8 months (95% CI 11.08–16.7). …”
Get full text

Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab by Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, Gil Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, Jan L. Bernheim, Bart Neyns

“…All cases of skin toxicity (N=8), hepatitis (N=1), colitis (N=3), and sarcoidosis (N=1) resolved without impact on HRQoL. …”
Get full text

Cryptococcosis in wait-listed liver transplant candidates: Prevalence, manifestations, and risk factors by Wan-Ting Tsai, Aristine Cheng, Yu-Chung Chuang, Cheng-Maw Ho, Yao-Ming Wu, Ming-Chih Ho, Hsin-Yun Sun, Ray-Hung Hu, Yee-Chun Chen

“…Results: Of the 377 candidates with a median MELD-Na score of 18, 84.4% had hepatitis B virus (HBV) infection. Cryptococcosis was diagnosed in 10 (2.6%) candidates, by CrAg in 6, culture in 2, or both in 2. …”
Get full text

Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients by Flaminia Ferri, Quirino Lai, Antonio Molinaro, Edoardo Poli, Lucia Parlati, Barbara Lattanzi, Gianluca Mennini, Fabio Melandro, Francesco Pugliese, Federica Maldarelli, Alessandro Corsi, Mara Riminucci, Manuela Merli, Massimo Rossi, Stefano Ginanni Corradini

“…No data are available on liver transplantation (LT) outcome and donor liver steatosis, classified as large droplet macrovesicular (Ld-MaS), small-droplet macrovesicular (Sd-MaS), and true microvesicular (MiS), taking into account the recipient Hepatitis C virus (HCV) status. Aim. We investigate the impact of allograft steatosis reclassified according to the Brunt classification on early graft function and survival after LT. …”
Get full text

Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective co... by Zhouwei Zhan, Bijuan Chen, Shaohua Xu, Ruyu Lin, Haiting Chen, Xiaohuan Ma, Xuanping Lin, Wanting Huang, Changhua Zhuo, Yu Chen, Zengqing Guo

“…Only one patient experienced a grade 4 TRAE (immune-related hepatitis), while the most common grade 3 TRAEs included thrombocytopenia, elevated aminotransferase levels, and neutropenia.ConclusionsThe combination of neoadjuvant chemotherapy, anti-angiogenic therapy, and ICIs has proven effective in treating LAGC patients, achieving high pCR rates and favorable survival outcomes while maintaining an acceptable safety profile.…”
Get full text

Alcohol abuse in gastroenterological patients by M. V. Mayevskaya, I. G. Bakulin, A. A. Chirkov, Ye. O. Lyusina, V. D. Lun’Kov

“…Thirty-two percent of patients had liver cirrhosis of toxic and viral etiology, 18% had chronic toxic and viral hepatitis, 11% - non-alcoholic fatty liver disease and various biliary diseases respectively, chronic pancreatitis and chronic gastritis subgroups represented 6% of all patients each, irritable bowel syndrome and gastroesophageal reflux disease - 4% each, primary biliary cirrhosis, hepatocellular carcinoma, stomach and duodenal peptic ulcer disease - 2%. …”
Get full text

Disproportionate Distribution of HBV Genotypes A and D and the Recombinant Genotype D/E in the High and Low HBV Endemic Regions of Uganda: A Wake-Up Call for Regional Specific HBV... by Hussein Mukasa Kafeero, Dorothy Ndagire, Ponsiano Ocama, Charles Drago Kato, Eddie Wampande, Henry Kajumbula, David Kateete, Abdul Walusansa, Ali Kudamba, Kigozi Edgar, Fred Ashaba Katabazi, Maria Magdalene Namaganda, Jamilu E. Ssenku, Hakim Sendagire

“…Background. Hepatitis B virus (HBV) is the leading cause of liver-related diseases. …”
Get full text

Management of Diabetes Mellitus in Patients with Chronic Liver Diseases by Yingying Zhao, Huichun Xing, Xiaomei Wang, Weini Ou, Hong Zhao, Ben Li, Yue Li, Ying Duan, Liwei Zhuang, Wei Li, Danying Cheng, Min Quan, Yu Zhang, Shibo Ji

“…According to a growing body of research, diabetes shows a close correlation with hepatitis, liver cirrhosis, and liver cancer. Moreover, coexistence of liver complications would accelerate the deterioration of patients with diabetes. …”
Get full text

Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus by Hatia RI, Hwang LY, Li R, Troisi C, Jalal PK, Amos CI, Gomez HF, Chun YS, Rashid A, Kaseb AO, Scheet PA, Hassan MM

“…Interactions among DM, heavy alcohol consumption, and viral hepatitis infection were examined. Overall survival was examined, and multivariable Cox proportional hazards regression analysis was performed for HCC patients with type 2 DM.Results: The adjusted odds ratio (AOR) for DM was 2.74 (P < 0.01). …”
Get full text

Supervised Injecting Room Cohort Study (SIRX): study protocol by Lisa Maher, Thomas Kerr, Matthew Hickman, Alexander Thompson, Peter Higgs, Paul Dietze, Paul A Agius, Nick Scott, Daniel O’Keefe, Mark A Stoové, Jack Stone, Dylan Vella-Horne, Ashleigh C Stewart, Amanda Roxburgh, Sione Crawford, Josephine Norman, Zachary Lloyd, Nico Clark

“…The two cohorts are: (1) participants drawn from the existing Melbourne Injecting Drug User Cohort Study (SuperMIX; established in 2008–ongoing) through which participants consent to annual behavioural surveys (including serological testing for HIV and hepatitis B and C viruses) and linkage to administrative data; and (2) the SIRX-Registration Cohort (SIRX-R; established in 2024) comprising registered MSIR clients who consent to a baseline behavioural survey and administrative data linkage including the frequency of SIF use, and the uptake of on-site services. …”
Get full text

Possible scenarios for the spread of mpox outside the endemic focus in Africa by Eskild Petersen, Ulrik Hvid, Oyewale Tomori, Anders Gorm Pedersen, Jacco Wallinga, Richard Pebody, Orlando Cenciarelli, Preben Aavitsland, David Van Laeken, Viggo Andreasen, Uffe Schneider, Julia Kinane Simonsen, Marlies Jilles Francine Goedknegt, Caroline Klint Johannesen, Jens D. Lundgren, Anders Koch, Bolette Søborg, Anna Mia Ekström, Hannah Nohynek, Frank M. Aarestrup, Tyra G. Krause, Lone Simonsen

Get full text